174 related articles for article (PubMed ID: 24224851)
1. X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.
Wu H; Xu C; Chen G; Wang J
J Gastroenterol Hepatol; 2014 May; 29(5):926-33. PubMed ID: 24224851
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis.
Xu J; Ma J; Zong HT; Wang SY; Zhou JW
Genet Mol Res; 2014 Mar; 13(1):1438-46. PubMed ID: 24634242
[TBL] [Abstract][Full Text] [Related]
3. Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis.
Cao Z; Song J; Wang J; Guo X; Yu S; Dong W
PLoS One; 2014; 9(1):e85357. PubMed ID: 24465544
[TBL] [Abstract][Full Text] [Related]
4. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.
Zhang X; Jiang LP; Yin Y; Wang YD
Tumour Biol; 2014 Jun; 35(6):5637-45. PubMed ID: 24590266
[TBL] [Abstract][Full Text] [Related]
5. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
7. X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis.
Zeng FR; Ling Y; Yang J; Tian XC; Yang X; Luo RC
Tumour Biol; 2013 Feb; 34(1):555-63. PubMed ID: 23188703
[TBL] [Abstract][Full Text] [Related]
8. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.
Gan Y; Li XR; Chen DJ; Wu JH
Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245
[TBL] [Abstract][Full Text] [Related]
9. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
[TBL] [Abstract][Full Text] [Related]
10. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B
BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic Association between
Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J
Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
Lv H; Li Q; Qiu W; Xiang J; Wei H; Liang H; Sui A; Liang J
Pathol Oncol Res; 2012 Oct; 18(4):1009-14. PubMed ID: 22549274
[TBL] [Abstract][Full Text] [Related]
13. Association of XRCC1 Arg399Gln Polymorphism with Colorectal Cancer Risk: A HuGE Meta Analysis of 35 Studies.
Forat-Yazdi M; Gholi-Nataj M; Neamatzadeh H; Nourbakhsh P; Shaker-Ardakani H
Asian Pac J Cancer Prev; 2015; 16(8):3285-91. PubMed ID: 25921133
[TBL] [Abstract][Full Text] [Related]
14. XRCC1 Arg399Gln polymorphism contributes to increased risk of colorectal cancer in Chinese population.
Tian Z; Li YL; Liu JG
Mol Biol Rep; 2013 Jul; 40(7):4147-51. PubMed ID: 23712778
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.
Shen X; Wang J; Yan X; Ren X; Wang F; Chen X; Xu Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1285-302. PubMed ID: 27154175
[TBL] [Abstract][Full Text] [Related]
16. The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: a systemic review and meta-analysis.
Qian YY; Liu XY; Pei D; Xu JL; Shen H; Chen XF; Liu YQ; Shen LZ; Shu YQ
Asian Pac J Cancer Prev; 2014; 15(22):9699-706. PubMed ID: 25520091
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
18. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
Liu YP; Ling Y; Zhang YP; Liu BR
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
[TBL] [Abstract][Full Text] [Related]
19. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
Li DJ; Xiao D
BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
[TBL] [Abstract][Full Text] [Related]
20. Association between the XRCC1 Arg399Gln polymorphism and risk of cancer: evidence from 297 case-control studies.
Yi L; Xiao-Feng H; Yun-Tao L; Hao L; Ye S; Song-Tao Q
PLoS One; 2013; 8(10):e78071. PubMed ID: 24205095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
